GlaxoSmithKline News and Research

RSS

HIV infection in mothers reduces disease resistance in babies: Study

New research suggests that babies whose mothers have HIV, but are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV.

13 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

Benson Group listed on 'Europe's 500' top growth companies

Europe's 500, the association of top European growth entrepreneurs met at the European Parliament in Brussels on February 3rd for the European Growth Summit 2011. An integral part of the event, the "Europe's 500" awards ceremony honoured the top-growth-companies in Europe, and released a list of the 200 fastest-growing, job-creating businesses.

10 Feb 2011

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

In response to increasing public enquiries for information on respiratory allergies, the Asthma Society of Canada announced today the launch of Allergies Count Too, NOW a program that will fill the gap in allergy education and provide critical information to Canadians.

9 Feb 2011

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.

7 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

Economist Conferences to holding 17th annual The Pharma Summit 2011 in London

Economist Conferences is holding its 17th annual The Pharma Summit 2011 in London on Thursday February 10 2011. The theme this year is 'Reinventing Pharma for a new generation' and will bring together over 150 senior executives from across the Pharma sector, including some of the industry's most influential names.

3 Feb 2011

Swine flu shots linked to narcolepsy: Investigation continues

The vaccine used against swine flu has been linked to a disorder called narcolepsy among those aged four to 19. Narcolepsy involves people falling asleep without warning or sleeping excessively in the daytime. A preliminary study also “observed [an] increase in incidence of narcolepsy” among those given the vaccine.

2 Feb 2011

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

GlaxoSmithKline is being sued this week by a French father-of-two, alleging the British pharmaceutical firm’s drug – Reqip (Ropirnirole) to treat Parkinson’s disease turned him into a gay sex and gambling addict. Parkinson’s disease is a seriously and progressively debilitating disease that leads to tremors, slowing of movements and ultimately total immobility.

1 Feb 2011

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Quest Diagnostics Incorporated today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics.

From Quest Diagnostics 1 Feb 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

McGill, GSK enter collaborative research agreement on cystic fibrosis

McGill University and GlaxoSmithKline plc have signed a collaboration agreement to develop a potential breakthrough approach to treat cystic fibrosis, a fatal genetic disease. The trans-Atlantic effort between researchers from McGill's Faculty of Medicine and their GSK collaborators in the UK, will focus on developing molecules that could treat the disease by correcting the dysfunction caused by the mutated gene.

28 Jan 2011

FDA issues Complete Response letter for Avodart sNDA for reduction of prostate cancer risk

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at increased risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

27 Jan 2011

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

26 Jan 2011

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

GlaxoSmithKline (GSK) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The Triad Group recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus that could potentially lead to life-threatening infections.

25 Jan 2011

GSK, Valeant receive European CHMP positive opinion for Trobalt

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™ (retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

21 Jan 2011

Routine rotavirus vaccine shows a significant drop in diarrhea cases: Study

A latest study has shown that the rotavirus vaccines have helped drastically reduce hospital visits around the world. Rotavirus can lead to fatal cases of diarrhea in children and causes half a million deaths in kids under five each year around the world. Developing countries are particularly at risk.

20 Jan 2011

GSK and Prosensa commence GSK2402968 Phase III study in DMD

GlaxoSmithKline and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.

20 Jan 2011

RTS,S offers 46 percent protection against malaria for at least 15 months after vaccination, Study finds

A Phase II trial published Friday in Lancet Infectious Diseases has shown that RTS,S, the "experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection" against malaria, Reuters reports.

18 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011